Hilde Furberg

Directeur/Membre du Conseil chez PCI BIOTECH HOLDING ASA Fortune : 5 322 $ au 31/08/2026

Profil

Ms. Hilde Furberg is an Independent Director at Herantis Pharma Oyj, an Independent Director at PCI Biotech Holding ASA and a SVP-Personalized Genetic Health Europe at Sanofi BV.
She is on the Board of Directors at Navamedic ASA, Sedana Medical AB, Herantis Pharma Oyj, PCI Biotech Holding ASA and Pluvia AS.
Ms. Furberg was previously employed as a Chairman by Blueprint Genetics Oy, an Independent Non-Executive Director by BerGenBio ASA, an Independent Non-Executive Director by Calliditas Therapeutics AB, a Non-Executive Director by Algeta ASA, an Independent Director by Aqualis ASA /Old/, a Senior Vice President & European Head-Rare Disease by Genzyme Corp., an Independent Director by Probi AB, a General Manager by Baxter Medical AB, a Head-Rare Diseases Europe by Genzyme Therapeutics Ltd., and a Partner by J&J Future Invest AS.
She also served on the board at OncoZenge AB, Larkberget AB, Tappin AS, Pronova BioPharma ASA, Copenhagen Capacity and Bio-Me AS.
She received her graduate degree from the University of Oslo.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
SEDANA MEDICAL AB 0%	31/12/2025	4 500 ( 0% )	5 322 $	31/08/2026

Postes actifs de Hilde Furberg

Sociétés	Poste	Début
PCI BIOTECH HOLDING ASA	Directeur/Membre du Conseil	01/05/2019
HERANTIS PHARMA OYJ	Directeur/Membre du Conseil	15/04/2021
SEDANA MEDICAL AB	Directeur/Membre du Conseil	01/01/2022
NAVAMEDIC ASA	Directeur/Membre du Conseil	23/04/2026
Pluvia AS	Directeur/Membre du Conseil	-
Genzyme Europe BV	Corporate Officer/Principal	14/10/2011

Anciens postes connus de Hilde Furberg

Sociétés	Poste	Fin
ONCOZENGE AB	Directeur/Membre du Conseil	21/08/2023
ONCOINVENT ASA	Président	06/01/2017
J&J Future Invest AS	Corporate Officer/Principal	13/11/2018
░░░░░░░ ░░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░░ ░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░